Cargando...
Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns
Immunotherapy combinations are used to improve outcomes in metastatic cancer, but evidence-based knowledge of appropriate starting doses for novel combinations is lacking. Phase I-III adult combination clinical trials (≥ 1 drug was immunotherapy; anti-PD-1, PD-L1, or CTLA-4) were reviewed (PubMed Ja...
Guardado en:
| Publicado en: | Oncoimmunology |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Taylor & Francis
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5593707/ https://ncbi.nlm.nih.gov/pubmed/28920006 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1338997 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|